Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 8:15:1484815.
doi: 10.3389/fendo.2024.1484815. eCollection 2024.

Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies

Jia-Xuan Huai #  1   2 , Fang Wang #  3 , Wen-Hui Zhang  1   2 , Yan Lou  1 , Gao-Xiang Wang  1 , Li-Ji Huang  1 , Jing Sun  1   2 , Xi-Qiao Zhou  1   2
Affiliations
Review

Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies

Jia-Xuan Huai et al. Front Endocrinol (Lausanne). .

Abstract

Medullary Thyroid Carcinoma (MTC), a neuroendocrine malignancy that arises from the calcitonin-secreting parafollicular C-cells of the thyroid, constitutes a minor yet impactful fraction of thyroid malignancies. Distinguished by its propensity for aggressive growth and a pronounced tendency for metastasis, MTC poses formidable obstacles to the early diagnosis and therapeutic intervention. The molecular genetics of MTC, particularly the role of the RET gene and the RAS gene family, have been extensively studied, offering insights into the pathogenesis of the disease and revealing potential therapeutic targets. This comprehensive review synthesizes the latest advancements in the molecular genetics of MTC, the evolution of precision therapies, and the identification of novel biomarkers. We also discuss the implications of these findings for clinical practice and the future direction of MTC research.

Keywords: RAS genes; RET gene; biomarkers; immunotherapy; medullary thyroid carcinoma; molecular genetics; multi-kinase inhibitors; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Wells SA, Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. (2015) 25:567–610. doi: 10.1089/thy.2014.0335 - DOI - PMC - PubMed
    1. Fagin JA, Wells SA, Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. (2016) 375:2307. doi: 10.1056/NEJMc1613118 - DOI - PubMed
    1. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, et al. . Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. (2007) 33:493–7. doi: 10.1016/j.ejso.2006.10.021 - DOI - PubMed
    1. Barletta JA, Nosé V, Sadow PM. Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocr Pathol. (2021) 32:35–43. doi: 10.1007/s12022-021-09664-3 - DOI - PMC - PubMed
    1. Falvo L, Catania A, Sorrenti S, D'Andrea V, Berni A, De Stefano M, et al. . Prognostic significance of the age factor in the thyroid cancer: statistical analysis. J Surg Oncol. (2004) 88:217–22. doi: 10.1002/jso.20140 - DOI - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources